Evidence map›Paper›PMID 38982075›Full record

ArticleNPJ breast cancer2024

Author Correction: Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.

Sara A Hurvitz, Aditya Bardia, Kevin Punie, Kevin Kalinsky, Lisa A Carey, Hope S Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu and 1 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ breast cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Sara A HurvitzClinical Research Division, Department of Medicine, UW Medicine, Fred Hutchinson Cancer Center, Seattle, WA, USA. shurvitz@fredhutch.org.ORCID http://orcid.org/0000-0001-7808-7191
Aditya BardiaMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Kevin PunieDepartment of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute and University Hospitals Leuven, Leuven, Belgium.
Kevin KalinskyWinship Cancer Institute, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-3113-7902
Lisa A CareyUniversity of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0003-2388-4649
Hope S RugoUniversity of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-6710-4814
Véronique DiérasCentre Eugène Marquis, Rennes, France.ORCID http://orcid.org/0000-0001-8094-4738
See PhanGilead Sciences Inc., Foster City, CA, USA.
Rosemary DelaneyGilead Sciences Inc., Foster City, CA, USA.
Yanni ZhuGilead Sciences Inc., Foster City, CA, USA.
Sara M TolaneyDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5940-8671

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID38982075
PMCPMC11233646

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.